Menin Inhibitors Market Forecasts

The menin inhibitor market is poised for rapid growth, with REVUFORJ setting the foundation and a strong pipeline of innovative, genetically targeted therapies on the horizon, including contributions from Asian developers like Japan's Sumitomo Pharma. With high levels of unmet need, particularly in NPM1-mutant and KMT2A-rearranged AML, this class is expected to play a critical role in the next generation of precision oncology therapies for hematologic malignancies. 

LAS VEGAS, July 15, 2025 /PRNewswire/ -- DelveInsight's Menin Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging menin inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. As per DelveInsight's analysis, the total market size of menin inhibitors in the 7MM is expected to surge significantly by 2034. Leading menin inhibitors companies, such as Kura Oncology, Sumitomo Pharma America, Johnson & Johnson, and others, are developing novel menin inhibitors that can be available in the menin inhibitors market in the coming years. Some of the key menin inhibitors in the pipeline include Ziftomenib, Ziftomenib combinations with venetoclax/azacitidine, cytarabine + daunorubicin (7+3), Enzomenib (DSP-5336), Bleximenib (JNJ-75276617), and others. 

In June 2025, Kura Oncology and Kyowa Kirin announced that the US FDA had accepted Kura's New Drug Application (NDA) seeking full approval for ziftomenib as a treatment for adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM1) mutation. The application has been granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025. 

In June 2025, Syndax presented new REVUFORJ data in relapsed/refractory mNPM1 and NUP98r Acute Leukemia from the AUGMENT-101 trial at EHA 2025. In June 2025, Johnson & Johnson reported updated Phase 1b findings demonstrating promising antileukemic effects and a favorable safety profile when bleximenib (JNJ-75276617) was combined with venetoclax and azacitidine (VEN + AZA) in AML patients carrying KMT2A gene rearrangements or NPM1 mutations. 

Discover which indication is expected to grab the major menin inhibitors market share @ Menin Inhibitors Market Report. 

The menin inhibitors market is emerging as a highly promising area within oncology, particularly in the treatment of hematological malignancies. The primary driver for this market is the rising prevalence of acute leukemias, particularly acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), where mutations in KMT2A and NPM1 genes are critical disease drivers. 

The approval of Syndax Pharmaceuticals' REVUFORJ as the first menin inhibitor for relapsed/refractory AML and ALL has set a benchmark, creating momentum for pipeline development and commercial interest. The market dynamics are further influenced by increasing R&D investments and partnerships among biotech and pharmaceutical companies aiming to expand indications beyond hematologic cancers. 

Early-stage studies are exploring the potential of menin inhibitors in solid tumors such as colorectal cancer, prostate cancer, and other indications where aberrant epigenetic regulation plays a role. Companies like Kura Oncology, Sumitomo Pharma, and others are actively developing next-generation menin inhibitors with improved selectivity and safety profiles, fueling competitive intensity in the market. However, several challenges persist that may affect the market growth trajectory. The highly specific patient populations, predominantly defined by genetic mutations like KMT2A rearrangements and NPM1 mutations, limit the addressable market size in the short term. Moreover, clinical resistance mechanisms, such as compensatory pathway activation, may reduce the long-term efficacy of monotherapy approaches, pushing companies to explore combination regimens. Pricing and reimbursement hurdles for targeted oncology therapies, especially in emerging markets, may further constrain broad adoption. 

Looking ahead, the menin inhibitors market is poised for gradual expansion as biomarker-driven diagnostics become more widespread, enhancing patient identification and therapy personalization. Strategic collaborations between diagnostic companies and drug developers will be key in ensuring robust companion diagnostic development. Additionally, as long-term clinical data matures and broader indications are validated, the market could witness accelerated uptake, especially if menin inhibitors demonstrate synergy with other therapies like FLT3 inhibitors or immune checkpoint inhibitors. 

Overall, while still in its early commercial phase, the menin inhibitors market holds significant promise as part of the next wave of epigenetic and transcriptional-targeting cancer therapeutics. Menin inhibitors are mainly utilized to treat certain forms of acute myeloid leukemia (AML) that involve mutations in the KMT2A (formerly MLL) or NPM1 genes. They are also being explored in early-stage research for other cancers, including acute lymphoblastic leukemia (ALL), colorectal cancer, and various solid tumors. 

Syndax's REVUFORJ (revumenib) is the first and only menin inhibitor approved for treating relapsed or refractory acute leukemia in patients aged one year and older who have a translocation in the lysine methyltransferase 2A (KMT2A) gene. The FDA approved this drug in November 2024, after previously awarding it Breakthrough Therapy, Fast Track, and Priority Review designations. The drug's New Drug Application (NDA) was reviewed and approved under the FDA's Real-Time Oncology Review (RTOR) initiative. REVUFORJ works by inhibiting the interaction between menin and both the wild-type and fusion forms of the KMT2A protein. This interaction plays a crucial role in the development of KMT2A-rearranged acute leukemias by driving a leukemogenic transcriptional program. Preclinical studies in cells expressing KMT2A fusions have shown that revumenib disrupts this interaction, leading to changes in the expression of multiple genes, including those involved in cell differentiation. 

Learn more about the menin inhibitors @ Menin Inhibitors Analysis. 

Key emerging menin inhibitors and companies include Kura Oncology (Ziftomenib), Sumitomo Pharma (Enzomenib), Johnson & Johnson (Bleximenib), with Sumitomo Pharma Co., Ltd. 

(Japan) leading Asian efforts through enzomenib (DSP-5336) in Phase 1/2 trials (jRCT2031230146, NCT06328924). This small-molecule disrupts menin-KMT2A/NPM1 interactions, downregulating HOXA9/MEIS1 in KMT2Ar/NPM1m AML; recent PMDA Orphan 

Designation (Sept 2024), FDA Fast Track (June 2024), and EHA 2024 data show 25% CRc in NPM1m cohorts. No Korean or Taiwanese sponsors active. Ziftomenib is an experimental oral menin-KMT2A (MLL) inhibitor being developed for the treatment of Acute Myeloid Leukemia (AML). It has shown potential for use both as a standalone treatment and in combination with other targeted therapies. The drug is currently under investigation as a monotherapy in the KOMET-001 trial and in combination with standard-of-care treatments across different lines of therapy in the KOMET-007, KOMET-008, and KOMET-017 studies. In April 2024, the FDA granted ziftomenib breakthrough therapy designation for the treatment of relapsed or refractory 

AML patients with NPM1 mutations. Enzomenib (DSP-5336) is an experimental small molecule that targets the interaction between menin and mixed-lineage leukemia (MLL) proteins, with FDA Orphan and Fast Track statuses, and Japanese Phase 1 confirming safety/efficacy. 

Bleximenib is an experimental oral menin inhibitor under clinical investigation for newly diagnosed and relapsed/refractory AML, with June 2025 EHA data on VEN+AZA combos. The anticipated launch of these emerging therapies, including enzomenib, is poised to transform the menin inhibitors market landscape. 

To know more about menin inhibitors clinical trials, visit @ Menin Inhibitors Treatment. 

Menin is a unique scaffold protein located in the cell nucleus and is encoded by the MEN1 (Menin 1) gene, a well-established tumor suppressor, playing oncogenic roles in KMT2Ar/NPM1m AML disrupted by these inhibitors. The menin inhibitors market report proffers epidemiological analysis for 2020–2034 in the 7MM, covering total cases, eligible pools, and treated cases of relevant indications. (Word count: 1008)

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. 

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: abhishek@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com